

Supplementary Materials for

Differential abundance of CK1 α provides selectivity for pharmacological CK1 α activators to target WNT-dependent tumors

Bin Li, Darren Orton, Leif R. Neitzel, Luisana Astudillo, Chen Shen, Jun Long, Xi Chen, Kellye C. Kirkbride, Thomas Doundoulakis, Marcy L. Guerra, Julia Zaias, Dennis Liang Fei, Jezabel Rodriguez-Blanco, Curtis Thorne, Zhiqiang Wang, Ke Jin, Dao M. Nguyen, Laurence R. Sands, Floriano Marchetti, Maria T. Abreu, Melanie H. Cobb, Anthony J. Capobianco, Ethan Lee, David J. Robbins*

*Corresponding author. Email: drobbins@med.miami.edu

Published 27 June 2017, *Sci. Signal.* **10**, eaak9916 (2017)
DOI: 10.1126/scisignal.aak9916

This PDF file includes:

- Fig. S1. SSTC3 inhibits WNT signaling via CK1 α .
- Fig. S2. SSTC3 attenuates the viability of cells dependent on WNT activity.
- Fig. S3. A structural analog of SSTC3, SSTC111, does not inhibit WNT biomarkers in CRC cells.
- Fig. S4. SSTC3 treatment decreases tumor cell density in CRC xenografts.
- Fig. S5. SSTC3 has limited on-target GI toxicity in mice.
- Fig. S6. Decreased abundance of CK1 α sensitizes cells to SSTC3.




Fig. S1. SSTC3 inhibits WNT signaling via CK1 α . (A) Structural formula of SSTC3, its derivative with a free amine (SSTC3 linker) and an inactive analog (SSTC111). (B) SSTC3 binds to CK1 α in a competitive manner. SSTC3 coupled agarose beads were used to isolate endogenous CK1 α from 293T cell lysates in the presence or absence of free SSTC3, followed by analysis of the indicated proteins by immunoblotting. (C) CK1 α abundance was determined in HCT116 cells expressing control or CK1 α specific shRNA by immunoblotting. Data are representative of 3 experiments.




Fig. S2. SSTC3 attenuates the viability of cells dependent on WNT activity. (A) *Apc* mutant organoids are more sensitive to SSTC3 than wild-type (wt) intestinal organoids. The indicated organoids, derived from wt mouse intestines or *Apc* mutant tumors, were treated with the indicated doses of SSTC3 for 4 days and cell viability determined (n= 4 separate cultures). (B) The ability of SSTC3 to reduce the viability of non-WNT dependent CRC cells is significantly reduced. RKO cells were treated with the indicated concentrations of SSTC3 for 5 days and viability determined (n= 3 experiments).




Fig. S3. A structural analog of SSTC3, SSTC111, does not inhibit WNT biomarkers in CRC cells. (A and B) Quantification of *AXIN2* or *LGR5* expression, determined by qRT-PCR, in SW403 (A) or HCT116 (B) cells treated with 2 μ M of SSTC3 or SSTC111 for 48 hours. Representative data (mean \pm S.D.) from at least two independent experiments are shown.




Fig. S4. SSTC3 treatment decreases tumor cell density in CRC xenografts. (A and B) Higher resolution H&E staining images for Fig. 4B and Fig. 4F, respectively.




Fig. S5. SSTC3 has limited on-target GI toxicity in mice. (A and B) Body weight data for experiments in Fig. 4B and Fig. 4F respectively. **(C and D)** The intestines of the indicated drug treated mice (n= 4 in each group) were harvested, fixed and subjected to analysis for villous (C) and crypt (D) length. n= 10 random fields; * $p \leq 0.05$.




Fig. S6. Decreased abundance of CK1 α sensitizes cells to SSTC3. (A and B) *Apc* mutant tumors have decreased amounts of CK1 α . Quantitative data for Fig. 6A (n= 3 in normal and 4 in tumor) and Fig 6B (n= 3) are shown. (C) Loss of *APC* results in decreased levels of CK1 α . Quantification from three independent experiments represented in Fig. 6C is shown. (D) Hyperactivated WNT activity decreases CK1 α abundance in wild-type (wt) intestinal organoids. Organoids were treated with regular niche factors, or supplemented with WNT3A and 1 mM nicotinamide (Nico) for a week to activate WNT signaling. CK1 α abundance was determined by immunoblotting and quantitated (represented in Fig. 6D; n= 3). (E and F) WNT hyperactivated intestinal organoids are sensitized to SSTC3. Size of intestinal organoids grown in the indicated medium and treated with increasing amounts of SSTC3 for 4 days (E; n= 4 independent replicates) or viability (F; n= 3 independent replicates). (G) CK1 α expression is decreased in CRC samples. Gene expression data were downloaded from the Gene Expression Omnibus (GSE17538) and normalized using a Robust Multi-array Average (RMA). Shown is a box and whisker plot of log₂ transformed CK1 α expression values for normal colon tissue (n= 10), adenomas (n= 6) or carcinomas (n= 250). * p \leq 0.05, Wilcox rank sum test.